At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
NT-501 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density
In Brief
A Phase 2 clinical trial evaluating NT-501 and Sham for Retinitis Pigmentosa and 2 related conditions. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsUniversity of California, San Francisco
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedFeb 2012
Primary CompletionJul 2019
TodayJul 2026
First PostedFeb 10, 2012
Enrollment StartJan 1, 2012
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 14.4 years ago
Interventions
NT-501drug
Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
Shamprocedure
Non-penetrating sham procedure to mimic implant procedure in the other eye.